A regulatory mechanism for RSK2 NH2-terminal kinase activity

Cancer Research

Volumn 69, Issue 10, 2009, Pages 4398-4406

  Cho, Yong Yeon ^a   Yao, Ke ^a   Pugliese, Angelo ^a   Malakhova, Margarita L ^a   Bode, Ann M ^a   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KAEMPFEROL; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RSK2 PROTEIN; S6 KINASE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; VALINE;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL STRAIN HCT116; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SEQUENCE HOMOLOGY; UPREGULATION; WESTERN BLOTTING;

BINDING SITES; CELL DIVISION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EPIDERMAL GROWTH FACTOR; HUMANS; KAEMPFEROLS; KINETICS; LYSINE; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASES; RECOMBINANT PROTEINS; REFERENCE VALUES; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SKIN; TETRADECANOYLPHORBOL ACETATE; TISSUE ARRAY ANALYSIS; VALINE;

EID: 66249107084     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4959     Document Type: Article

References (34)

1. Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000;19:6594-6599 (Pubitemid 32197697)
2. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004;68:320-344 (Pubitemid 38756868)
3. Jones SW, Erikson E, Blenis J, Maller JL, Erikson RL. A Xenopus ribosomal protein S6 kinase has two apparent kinase domains that are each similar to distinct protein kinases. Proc Natl Acad Sci U S A 1988;85:3377-3381 (Pubitemid 18199262)
4. Frodin M, Jensen CJ, Merienne K, Gammeltoft S. A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1. EMBO J 2000;19:2924-2934 (Pubitemid 30386764)
5. Frodin M, Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 1999;151:65-77. (Pubitemid 29278816)
6. Nebreda AR, Gavin AC. Perspectives: signal transduction. Cell survival demands some RSK. Science 1999;286:1309-1310
7. Xing J, Ginty DD, Greenberg ME. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 1996;273:959-963 (Pubitemid 26275173)
8. Sassone-Corsi P, Mizzen CA, Cheung P, et al. Requirement of RSK-2 for epidermal growth factor-activated phosphorylation of histone H3. Science 1999;285:886-891 (Pubitemid 29381988)
9. Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci U S A 1993;90:5889-5892 (Pubitemid 23191418)
10. Davis RJ. Transcriptional regulation by MAP kinases. Mol Reprod Dev 1995;42:459-467
11. Ward GE, Kirschner MW. Identification of cell cycle-regulated phosphorylation sites on nuclear lamin C. Cell 1990;61:561-577 (Pubitemid 20169013)
12. Yang X, Matsuda K, Bialek P, et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry syndrome. Cell 2004;117:387-398 (Pubitemid 38534544)
13. Cho YY, He Z, Zhang Y, et al. The p53 protein is a novel substrate of ribosomal S6 kinase 2 and a critical intermediary for ribosomal S6 kinase 2 and histone H3 interaction. Cancer Res 2005;65:3596-3603 (Pubitemid 40616335)
14. Cho YY, Yao K, Bode AM, et al. RSK2 mediates muscle cell differentiation through regulation of NFAT3. J Biol Chem 2007;282:8380-8392 (Pubitemid 47093615)
15. Pearson G, English JM, White MA, Cobb MH. ERK5 and ERK2 cooperate to regulate NF-κB and cell transformation. J Biol Chem 2001;276:7927-7931 (Pubitemid 37385589)
16. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999;19:2435-2444 (Pubitemid 29144487)
17. Cho YY, Bode AM, Mizuno H, et al. A novel role for mixed-lineage kinase-like mitogen-activated protein triple kinase a in neoplastic cell transformation and tumor development. Cancer Res 2004;64:3855-3864 (Pubitemid 38697296)
18. Bonni A, Brunet A, West AE, et al. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999;286:1358-1362 (Pubitemid 129516237)
19. Clark DE, Errington TM, Smith JA, et al. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res 2005;65:3108-3116 (Pubitemid 40524591)
20. David JP, Mehic D, Bakiri L, et al. Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J Clin Invest 2005;115:664-672 (Pubitemid 40322240)
21. Smith JA, Poteet-Smith CE, Xu Y, et al. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 2005;65:1027-1034 (Pubitemid 40216465)
22. Cho YY, Yao K, Kim HG, et al. Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res 2007;67:8104-8112 (Pubitemid 47395145)
23. Nguyen TL, Gussio R, Smith JA, et al. Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore. Bioorg Med Chem 2006;14:6097-6105 (Pubitemid 44080569)
24. Ikuta M, Kornienko M, Byrne N, et al. Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: implications for the design of RSK1 specific inhibitors. Protein Sci 2007;16:2626-2635 (Pubitemid 350172748)
25. Zhong SP, Ma WY, Dong Z. ERKs and p38 kinases mediate ultraviolet B-induced phosphorylation of histone H3 at serine 10. J Biol Chem 2000;275:20980-20984 (Pubitemid 30481785)
26. Jacquot S, Merienne K, De Cesare D, et al. Mutation analysis of the RSK2 gene in Coffin-Lowry patients: extensive allelic heterogeneity and a high rate of de novo mutations. Am J Hum Genet 1998;63:1631-1640 (Pubitemid 30415725)
27. Miean KH, Mohamed S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agric Food Chem 2001;49:3106-3112
28. Day AJ, DuPont MS, Ridley S, et al. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver β-glucosidase activity. FEBS Lett 1998;436:71-75 (Pubitemid 28454609)
29. Walle T. Absorption and metabolism of flavonoids. Free Radic Biol Med 2004;36:829-837
30. DuPont MS, Day AJ, Bennett RN, Mellon FA, Kroon PA. Absorption of kaempferol from endive, a source of kaempferol-3-glucuronide, in humans. Eur J Clin Nutr 2004;58:947-954 (Pubitemid 38923194)
31. Nguyen TT, Tran E, Ong CK, et al. Kaempferol-induced growth inhibition and apoptosis in A549 lung cancer cells is mediated by activation of MEK-MAPK. J Cell Physiol 2003;197:110-121 (Pubitemid 37486233)
32. Nakamura Y, Chang CC, Mori T, et al. Augmentation of differentiation and gap junction function by kaempferol in partially differentiated colon cancer cells. Carcinogenesis 2005;26:665-671 (Pubitemid 41214158)
33. Ackland ML, van de Waarsenburg S, Jones R. Synergistic antiproliferative action of the flavonols quercetin and kaempferol in cultured human cancer cell lines. In Vivo 2005;19:69-76. (Pubitemid 40450379)
34. Bode AM, Dong Z. Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci STKE 2003;2003:RE2.